Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Divalent Metal Transporter 1 (DMT1), also known as NRAMP2, DCT1, or SLC11A2, is a proton-coupled symporter responsible for the transport of divalent metal ions across cellular membranes. Its primary function is the uptake of ferrous iron (Fe²⁺), but it can also transport other metals like manganese, cadmium, cobalt, nickel, vanadyl, and lead. DMT1 plays a crucial role in intestinal iron absorption and cellular iron acquisition, particularly in erythroid precursor cells. Expression is regulated by systemic iron levels, and mutations can cause severe anemia. It is explored as a therapeutic target for diseases associated with pathological iron overload.
Pharmacological inhibition of DMT1
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Divalent Metal Transporter 1 (DMT1).